Proactive Investors - Run By Investors For Investors

Redx Pharma exploring options with interested parties for its NBTI programme after Deinove declines to exercise option

The AIM-listed group said the decision by Deinove follows a period of nine months of evaluation during which it had sole rights to develop the Novel Bacterial Topoisomerase Inhibitor programme
Drug testing
It added that all rights to the NBTI programme, including all new data generated by Deinove, now revert to Redx

Redx Pharma Plc (LON:REDX) is exploring options for Novel Bacterial Topoisomerase Inhibitor (NBTI) programme with other parties potentially interested in licensing the project after Deinove said it has decided not to exercise their option.

The AIM-listed drug discovery and development company focused on cancer and fibrosis said the decision by Deinove follows a period of nine months of evaluation during which the group had sole rights to develop the programme.

WATCH: Redx Pharma receives approval to re-commence clinical trial of RXC004

The group added that all rights to the NBTI programme, including all new data generated by Deinove, now revert to Redx.

The firm entered into an option and license agreement with Deinove for the NBTI programme in March 2018 following a strategic decision to close the Redx anti-infectives unit in 2017, and focus on developing new medicines in Oncology and Fibrosis. 

Last week, Redx announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval to the company to re-commence the phase 1/2a trial for RXC004, an oral porcupine inhibitor targeting the Wnt signalling pathway.

It said clinical evaluation of RXC004 in patients with advanced solid tumours remains on track to resume in H1 2019 following the approval of a revised phase 1/2a clinical trial protocol and drug formulation.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use